

Cell Factory Group @ Ri.MED

The Cell Factory group, including Ri.MED and ISMETT personnel, aims at the production, quality control and release of Advanced Therapy Medical Products (ATMPs) for clinical use, which are prepared at ISMETT Good Manufacturing Practice (GMP) Facility.





FOCUS

- Cell based therapies for end stage organ failure (e.g. based on MSCs)
- Immunotherapies, e.g. Multivirus specific T lymphocytes



OUTCOME

- Equipment, Facility and method validation protocols
- Optimized production processes
- Validated QC methods for different products
- Support to clinicians for non-repetitive use of ATMPs on single patients



COLLABORATIONS

- The Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), Palermo, ITA
- ISMETT- IRCCS policlinico San Matteo, Pavia, ITA
- ISMETT-IRCCS Ospedale Galeazzi- Sant'Ambrogio, ITA
- University of Pittsburgh, USA



AIMS

- Contribute to translational medicine, providing new ATMPs to patients
- ATMPs release for Phase I studies and single patient use
- Optimization/automation of production processes and Quality Control (QC) tests



EXPERTISE AND RESOURCES

EXPERTISE:

- Definition and validation of GMP compliant processes and QC tests
- Production of cell therapies and QC testing
- Maintenance of a Good Manufacturing Practice compliant Quality Assurance system
- Cell product banking

RESOURCES:

- Fully equipped and qualified GMP facility and QC Lab (to be authorized by AIFA for the single ATMPs productions)



Fondazione
Ri.MED

www.fondazionerimed.eu

Cell Factory Group

c/o The Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT)
Via Ernesto Tricomi 5 - 90127, Palermo, Italy

Qualified Person: Chiara Di Bartolo, MSc
cdibartolo@fondazionerimed.com